Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Lewis Asset Management LLC

Lewis Asset Management LLC lifted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 42.5% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 66,308 shares of the company’s stock after acquiring an additional 19,775 shares during the period. Intellia Therapeutics makes up approximately 1.0% of Lewis Asset Management LLC’s investment portfolio, making the stock its 19th largest holding. Lewis Asset Management LLC owned 0.07% of Intellia Therapeutics worth $1,363,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. ARK Investment Management LLC grew its stake in Intellia Therapeutics by 5.7% during the 3rd quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after purchasing an additional 659,651 shares during the last quarter. Vanguard Group Inc. boosted its position in Intellia Therapeutics by 8.9% in the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock valued at $250,168,000 after buying an additional 746,263 shares during the last quarter. Federated Hermes Inc. raised its position in Intellia Therapeutics by 19.2% during the 2nd quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock worth $51,494,000 after buying an additional 371,189 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Intellia Therapeutics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after acquiring an additional 98,865 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Intellia Therapeutics by 0.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 364,306 shares of the company’s stock valued at $8,153,000 after acquiring an additional 2,301 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

NTLA stock opened at $16.00 on Friday. Intellia Therapeutics, Inc. has a 1 year low of $13.95 and a 1 year high of $34.87. The firm has a market capitalization of $1.63 billion, a PE ratio of -2.92 and a beta of 1.81. The business has a 50 day simple moving average of $19.28 and a 200-day simple moving average of $22.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The firm had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. During the same quarter last year, the firm posted ($1.40) earnings per share. The company’s revenue was down 48.5% on a year-over-year basis. On average, equities research analysts expect that Intellia Therapeutics, Inc. will post -5.21 EPS for the current year.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the sale, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 3.20% of the company’s stock.

Wall Street Analysts Forecast Growth

NTLA has been the subject of a number of research reports. Robert W. Baird decreased their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada restated an “outperform” rating and issued a $54.00 target price on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Wedbush reissued a “neutral” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a report on Thursday. JPMorgan Chase & Co. dropped their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Finally, Evercore ISI upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $58.13.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.